In NSCLC, miR-7 has been reported to suppress tumorigenesis by targeting a number of important proto-oncogenes, including EGFR, IRS1 (insulin receptor substrate 1), IRS2, RAF1 (v-raf-1 murine leukemia viral oncogene homologue 1), and PAK1 (p21/CDC42/RAC1-activated kinase 1), and by inhibiting EGFR/AKT pathway activation (30–33). This evidence concerns the gene RAF1 and non-small cell lung carcinoma.